The Importance of Preventing Biosimilar Disparagement

The Importance of Preventing Biosimilar Disparagement

Speaking Engagement

Competition is critical for the healthcare industry. Biosimilars could offer significant cost savings and enhanced consumer choice. However, it is argued that disparagement of biosimilars could foster negative misconceptions, cause confusion, and discourage their uptake. This panel will discuss whether disparagement could potentially violate antitrust law as well as consumer protection laws.

WilmerHale's Holly Ovington will moderate this ABA Antitrust Section panel discussion on disparagement of biosimilars. 

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.